Published in Med Microbiol Immunol on January 09, 2015
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Staged Phase I/II Hepatitis C Prophylactic Vaccine | NCT01436357
Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus. Wellcome Open Res (2016) 0.78
HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. J Infect Dis (2015) 0.78
Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep (2016) 0.75
Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations. PLoS One (2016) 0.75
Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS(®) Ampliprep/COBAS(®)TaqMan HBV test v2.0. Med Microbiol Immunol (2017) 0.75
Drugs in Development for Hepatitis B. Drugs (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
IL-10: the master regulator of immunity to infection. J Immunol (2008) 6.11
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
T cells and viral persistence: lessons from diverse infections. Nat Immunol (2005) 4.12
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist (2007) 4.01
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology (2009) 3.07
Local control of the immune response in the liver. Immunol Rev (2000) 3.01
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol (2003) 2.50
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol (2004) 2.28
IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med (2008) 2.20
GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology (2013) 2.14
Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol (2005) 2.06
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology (2009) 1.88
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology (2011) 1.85
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology (2014) 1.66
Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol (2003) 1.64
IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol (2012) 1.47
Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology (2004) 1.28
Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther (2006) 1.25
The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog (2013) 1.23
New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov (2013) 1.22
Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog (2014) 1.16
Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog (2013) 1.16
Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine (2005) 1.15
A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One (2008) 1.14
HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int (2009) 1.13
Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol (2013) 1.12
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A (2013) 1.10
Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol (2001) 1.09
DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology (2001) 1.08
Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol (2007) 1.06
Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. J Virol (2013) 1.01
The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology (2007) 1.00
Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection (2003) 0.98
Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis (2009) 0.97
Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology (2012) 0.96
Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One (2011) 0.90
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Gastroenterology (2014) 0.89
A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat (2012) 0.88
Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium. Retrovirology (2013) 0.87
HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells. J Clin Immunol (2003) 0.86
Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther (2012) 0.85
The lack of effect of therapeutic vaccination with a pre-S2/S HBV vaccine in the immune tolerant phase of chronic HBV infection. J Clin Gastroenterol (2003) 0.81
New approaches in HIV eradication research. Curr Opin Infect Dis (2011) 0.79
Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients. J Gastroenterol Hepatol (2002) 0.78
Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology (1993) 0.77
Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B. PLoS One (2014) 0.75